HumeCare+ Review: Measures The Muscle, Hides The Price

The one-sentence version

HumeCare+ is the prescribing arm of a body-composition device company, and it does one thing no other program in this ranking does — it measures whether you are losing fat or muscle, every week, and adjusts the dose against that — while doing one thing worse than almost anyone here: it publishes no price at all until you have handed over a medical history.

What it sells

Compounded semaglutide, by injection or orally, and compounded tirzepatide blended with vitamin B12 and glycine. That is the whole menu — this is not a longevity clinic with a shelf of peptides, it is a single-purpose GLP-1 program.

What arrives with the medication is the reason it is graded here: a Hume Pod body analyzer, described by the company as a $350 device included at no extra cost, reading fat mass, lean muscle and metabolic age weekly, with the data going to the clinical team.

Why that matters on a longevity site

Lean mass is not a cosmetic concern. It predicts physical function, insulin sensitivity and fracture risk decades out, and it is the specific thing a rapid weight-loss drug erodes: meta-analyzes of incretin therapies put lean tissue at roughly a quarter to a third of total weight lost.

The standard telehealth answer to that is a sentence of reassurance. A scale cannot tell fat from muscle, so a program watching only weight cannot know which it is taking. Measuring the split weekly and titrating on it is a materially different design, and the glycine and B-vitamin adjuncts are pointed at the same problem rather than sold as an upsell.

★ It also publishes its own average result rather than only its ceiling: a footnote states the headline came from the top 25th percentile of 1,185 users and that average loss was 13 pounds. That is rarer than it should be, and it is why the criticisms below are worth taking seriously rather than discounting.

The pricing problem

Nothing on the public site carries a figure. Past the medical questionnaire, compounded semaglutide is $199 a month and tirzepatide $299, both billed monthly with no minimum term — genuinely better than the three- and six-month prepays this category runs on.

But that $199 is a floor, not a price. The terms charge a "clinical consultation fee assessed at enrollment and each refill", non-refundable, collected for a separate Clinical Network, and never state what it is. The same document reserves the right to charge more: "medications, dosages, formulations ... may be subject to additional charges outside the membership fee at Hume's sole discretion." No published number totals this program.

⚠ The guarantee narrows between the marketing and the contract. The landing page promises 180 days money back. Section 8A of the terms gives 90 days, pays out only if you achieved no measurable weight loss at all, excludes that consultation fee "under all circumstances", requires every dose logged and all 13 weigh-ins, and excludes anyone who has previously taken a GLP-1.

What is never published

No pharmacy is named and no 503A or 503B classification is stated anywhere. Hume describes itself as a platform; prescribing sits with a separate Clinical Network under its own patient agreements, and the terms state plainly that Hume does not guarantee you will be prescribed anything.

There is also no milligram figure on any surface — including the checkout, which says only that the provider sets the final dose. The page selling the program is titled a microdose program, so a product named for its dose never states one.

The grade

The measurement is real and, on this ranking's terms, valuable: it is the only program here that treats lean mass as a number to manage rather than a risk to mention. Against that sits a pricing structure you cannot total before committing a medical history, an unquantified recurring fee, and a guarantee that is materially narrower in the contract than in the advertising. We are not paid by HumeCare, and the link below goes to its own page.